| Features: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sanguinarine (SANG) — a benzophenanthridine alkaloid isolated primarily from Sanguinaria canadensis (bloodroot) and other Papaveraceae species. Potent redox-active, DNA-intercalating phytochemical studied extensively in preclinical oncology. Primary mechanisms (conceptual rank): Bioavailability / PK relevance: Limited human PK data; rapid reactivity and protein binding likely restrict systemic exposure. Toxicity (oral mucosal injury, cytotoxicity) limits therapeutic window. In-vitro vs oral exposure: Many anti-cancer effects occur at micromolar concentrations unlikely achievable systemically via safe oral dosing (qualifier: high concentration only for direct cytotoxicity). Clinical evidence status: Preclinical oncology only; no validated RCT cancer indication. Safety concerns limit development. Extracted from bloodroot plant from whose scientific name, Sanguinaria canadensis, its name is derived; the Mexican prickly poppy; Chelidonium majus; and Macleaya cordata.Sanguinarine — Cancer vs Normal Cell Pathway Map
TSF legend: |
| Source: |
| Type: |
| MAPK3 (ERK1) ERK proteins are kinases that activate other proteins by adding a phosphate group. An overactivation of these proteins causes the cell cycle to stop. The extracellular signal-regulated kinase (ERK) signaling pathway is a crucial component of the mitogen-activated protein kinase (MAPK) signaling cascade, which plays a significant role in regulating various cellular processes, including proliferation, differentiation, and survival. high levels of phosphorylated ERK (p-ERK) in tumor samples may indicate active ERK signaling and could correlate with aggressive tumor behavior EEk singaling is frequently activated and is often associated with aggressive tumor behavior, treatment resistance, and poor outcomes. |
| 1090- | SANG, | Sanguinarine inhibits invasiveness and the MMP-9 and COX-2 expression in TPA-induced breast cancer cells by inducing HO-1 expression. |
| - | in-vitro, | BC, | MCF-7 |
| 1210- | SANG, | Sanguinarine combats hypoxia-induced activation of EphB4 and HIF-1α pathways in breast cancer |
| - | in-vitro, | BC, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:147 Target#:105 State#:% Dir#:1
wNotes=0 sortOrder:rid,rpid